NIBSC has a portfolio of reference and research reagents to support areas of diagnostics, vaccine development and research on COVID-19 and SARS-CoV-2.
Details are provided below to guide you to the materials most suitable to your needs. Further information is available in the Instructions for Use document associated with each material which can be accessed by clicking on the relevant NIBSC code.
We are currently seeking partners for sourcing serum or plasma from vaccinated individuals and/or recovered patients for the development of working standards for each of the SARS-CoV-2 variants of concern. View further information and application details here.
To order any of these reagents, please first ensure that you have set up an account with us and then select the NIBSC code from the list below.
First WHO International Standard for SARS-CoV-2 RNA (NIBSC code: 20/146)
Material: Inactivated virus, WHO IS
Intended use: Primary calibrant for molecular assays based on nucleic acid amplification techniques
Description: Acid-heat inactivated SARS-CoV-2 virus, formulated in a TRIS buffer with human serum albumin, trehalose and human genomic DNA. Non-Infectious. Requires extraction prior to downstream application.
First WHO International Standard for anti-SARS-CoV-2 immunoglobulin, human (NIBSC code: 20/136)
Material: Antibody, human, convalescent plasma, WHO IS
Intended use: Primary calibrant for serological assays
Description: Pool of convalescent plasma from recovered COVID-19 patients, containing high titre antibodies against SARS-CoV-2. Plasma has been solvent detergent treated to minimise the risk of presence of enveloped viruses.
First WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin, human (NIBSC code: 20/268)
Material: Antibody, human, convalescent plasma, WHO reference panel
Intended use: Serological assay development and evaluation, Vaccine evaluation, Research,
Anticipated delivery date: comprises of 5 panel members; four pools of convalescent plasma from recovered COVID-19 patients, containing high, medium, low anti-S but relatively high anti-N, low antibodies against SARS-CoV-2, and a negative control, pool of plasma from healthy donors collected before 2019.
Anti-SARS-CoV-Verification Panel for Serology Assays (NIBSC code: 20/B770)
Material: Antibody, human, convalescent plasma Anti-SARS-CoV-2 negative plasma
Intended use: Diagnostics laboratories, Assay manufacturers
Description: Anti-SARS-CoV-2 Verification Panel for Serology Assays. Contains 23 Ant-SARS-CoV-2 positive samples of varying reactivity and antibody composition & 14 Anti-SARS-CoV-2 negative samples. The panel is CE-marked under ISO 13485 and is intended to verify manufacturer’s claims in compliance with ISO 15189.
Anti-SARS-CoV-2 Antibody Diagnostic Calibrant (NIBSC code: 20/162)
Material: Antibody, human, convalescent plasma
Intended use: Diagnostic laboratories, Assay manufacturers, Diagnostic Serological Calibrant
Description: High titre Anti-SARS-CoV-2 antibody positive material used to assess and compare the relative sensitivities for Anti-Sars-CoV-2 antibody assays by end-point dilution.
External Quality Control reagent for anti-SARS-CoV-2 antibody (NIBSC code: 20/B764)
Material: Antibody, human, convalescent plasma, CE-marked
Intended use: Diagnostics laboratories Quality Control reagent
Description: External Quality Control to monitor the assay performance, equipment and operators on a run to run or day to day basis. CE marked under ISO 13485. Fulfils the requirements of a reference material as described in ISO 15189.
Material: RNA, armoured, CE-marked.
Intended use: Diagnostics laboratories - Run control designed to ensure the fidelity and reproducibility of molecular assays.
Description: In-assay performance monitoring of both the assay and operators on a day to day basis. CE marked under ISO 13485. Fulfils the requirements of a reference material as described in ISO 15189.
Research reagent for SARS-CoV-2 RNA (NIBSC code: 19/304)
Material: RNA, armoured
Intended use: Assay development, Research - Molecular assay development; positive control for nucleic acid amplification-based assays.
Description: Chimaeric HIV-like particles containing SARS-CoV-2 RNA, formulated in a TRIS buffer with human serum albumin and trehalose. Non-infectious. Requires extraction prior to downstream amplification.
Related materials for research use
The materials listed below are available from the Centre for Aids Reagents (CFAR) and are intended for research use only. They can be ordered following the completion of a Material Transfer Agreement. Please contact email@example.com if you require assistance or have any additional enquiries about these materials.
Rabbit antiserum to SARS-CoV-1 S1 (CFAR #4024)
mAb to SARS-CoV-2 Nucleocapsid protein (CR3009 Hu) (CFAR #101009)
mAb to SARS-CoV-2 Nucleocapsid protein (CR3018 Hu) (CFAR #101010)
mAb to SARS-CoV-2 Nucleocapsid protein (CR3009 Mu) (CFAR #101011)
HEK293T-ACE2-TMPRSS2 (CFAR #101008)
VeroE6/TMPRSS2 (CFAR #100978)
A549-ACE2 Clone 8 (CFAR#101005)
A549-ACE2 Clone 8-TMPRSS2 (CFAR#101006)
pI.18-SARS-CoV-2-spike-B.1.1.7 (CFAR #101023)
pI.18-SARS-CoV-2-spike-B.1.351 (CFAR #101024)
pCAGGS_SARS-CoV-2_Spike (CFAR #100976)
pCAGGS_SARS_CoV2_D614G_Spike (CFAR #100985)
pCAGGS_SARS_CoV2_Bristol-Deletion_Spike (CFAR #100986)
SARS-CoV-2 Trimeric Spike (CFAR #101007)
SARS-CoV-2 RBD (CFAR #100981)
SARS-CoV-2 N (CFAR #100982)
SARS-CoV-1 S1 (CFAR#0688)
Purified RNA extracts from BetaCoV/Australia/VIC01/2020 (CFAR#100988)
SARS-CoV-2 VOC202012/02 (B.1.351 lineage) P4 (CFAR #101022)
SARS-CoV-2 VOC202012/01 (B.1.1.7. lineage) (Acid/heat inactivated) (CFAR #101027)
BetaCoV/Australia/VIC01/2020 (4% formaldehyde inactivated) (CFAR #101025)
BetaCoV/Australia/VIC01/2020 (0.01% formaldehyde inactivated) (CFAR #101026)
SARS-CoV-2 VOC202012/01 (B.1.1.7. lineage) P4 (CFAR#101019)
BetaCoV/Australia/VIC01/2020 (inactivated) (CFAR#100987)
BetaCoV/Australia/VIC01/2020 (CFAR #100980)
SARS-CoV-2 infectious virus (CVR-GLA1) (CFAR#100998)
SARS-CoV-2 infectious virus (CVR-GLA 2) (CFAR#100999)
SARS-CoV-2 infectious virus (CVR-GLA 3) (CFAR#101000)